AVEO Pharmaceuticals is a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines for patients with cancer. Co.'s product candidates include: Tivozanib, which is for the treatment of renal cell carcinoma, hepatocellular carcinoma, immunologically cold tumors and cholangiocarcinoma; Ficlatuzumab, which is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor; AV-380, which is a humanized IgG1 monoclonal antibody that targets growth differentiation factor 15; AV-203, which is a humanized IgG1 monoclonal antibody that targets ErbB3; and AV-353, which is a IgG1 monoclonal antibody that targets the Notch 3 pathway.
|
Free AVEO Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Hold (2.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Analysts' Target Price: AVEO Stock Forecast Based on Zacks ABR data; powered by Xignite |